Buprenorphine or methadone: shared decision

A woman in her forties comes to the outpatient clinic after months of thinking about it. She has used opioids for years, works shifts, cares for two children and has already tried to stop on her own several times. In the consultation, the resident presents the two options with the confidence of someone who has studied: "buprenorphine is safer, methadone retains better". She listens, nods and asks just one thing: "which one lets me keep working?". The question shows that the decision was not where the resident thought it was.

NEXO is a daily medical diagnosis game: one clinical case a day, up to six progressive clues, and ICD-10 proximity feedback across five levels.

This text treats the choice between buprenorphine and methadone as a shared decision problem. The focus is on how the student and the resident organize the evidence, find out what matters to the person and turn the two things into a choice she can sustain. Doses, regimens and local dispensing rules are left to your service's guideline. Starting buprenorphine and the physiological reasoning about precipitated withdrawal are the subject of another post in the series; here the question is which path to choose, and how to choose together.

Key points

• Both medications are effective treatment for opioid use disorder and are associated with lower mortality while the person is in treatment.
• The differences between them are real, but small enough that values, routine and preferences weigh as much as the evidence.
• Shared decision making is a process with steps: present the choice, explain the options and find out preferences before deciding.
• Retention in treatment is the outcome that most changes the person's life; the best medication is often the one she can stay on.
• The periods of entering and leaving treatment concentrate risk, and this needs to be part of the conversation.
• Non-stigmatizing language changes the quality of the decision and the trust in the relationship.

Why this is a preference-sensitive decision

Some clinical decisions have a clearly better answer for almost everyone. Others have two or more reasonable options, with advantages and disadvantages that weigh differently for different people. These are called preference-sensitive decisions, and the choice between buprenorphine and methadone is a typical example.

The World Health Organization guidance on assisted pharmacological treatment of opioid dependence recommends both as maintenance options and treats the choice as something that should take into account the person's situation and the service context (WHO, 2009). The NICE technology appraisal followed the same line and recommended that the decision consider individual circumstances and patient preference (NICE TA114).

What changes when the decision is preference-sensitive

When two options are reasonable, the question stops being "which is the best medication?" and becomes "which is the best medication for this person, now?". The post on clinical decision making shows how to weigh benefits and risks in general approaches. Here, the weight of each factor depends on who is sitting in front of you.

The role of the student and the resident

Those in training are often the ones with more consultation time and less confidence about the decision. It is common to offset insecurity with a firm recommendation. The more useful alternative is to organize the conversation: make it clear that there is a choice, explain the options honestly and find out what matters to the person. This organization is a clinical skill, and it can be learned.

What the evidence says, without oversimplifying

Before sharing the decision, you need to understand the evidence well. Oversimplifying leads to sentences that sound correct and inform poorly.

Retention and opioid use

The Cochrane review that compared buprenorphine and methadone in maintenance found that, in flexible-dose regimens, buprenorphine retained fewer people in treatment than methadone. At fixed medium and high doses, the difference in retention and in suppression of heroin use no longer appeared (Mattick et al., 2014). This means that the sentence "methadone retains better" depends on how the two are managed.

The previous review of the same group showed that methadone is superior to treatments without substitution for keeping people in treatment and reducing heroin use (Mattick et al., 2009). The two pieces of evidence, together, support that both are effective treatment and that how it is conducted matters.

Mortality

A systematic review with meta-analysis of cohorts showed that the risk of death is much lower during treatment with methadone or buprenorphine than outside it, and that the periods right after starting methadone and right after leaving treatment concentrate risk (Sordo et al., 2017). A more recent meta-analysis reinforced the association between being in agonist treatment and lower all-cause and overdose mortality (Santo et al., 2021).

Outcomes in real-world services

In a large cohort of services in the United States, treatment with buprenorphine or methadone was associated with fewer overdoses and fewer opioid-related hospitalizations than other treatment paths (Wakeman et al., 2020). For reasoning, the message is that the difference between the two medications is usually smaller than the difference between treating and not treating.

Pharmacology that helps explain

Buprenorphine is a partial agonist with high affinity for the mu receptor, which produces a ceiling effect on respiratory depression (Walsh et al., 1994). Methadone is a full agonist, with a long and variable half-life. Reviews on the treatment of opioid use disorder summarize these differences and how they translate into safety and follow-up routine (Bell and Strang, 2020). For the conversation, pharmacology becomes plain language: one has a larger safety margin for breathing; the other may control intense craving better in people with heavy use, but requires more care at the start.

The shared decision model in three conversations

A practical model, widely used in teaching, describes shared decision making in three conversations: the choice talk, the option talk and the decision talk (Elwyn et al., 2012). It helps organize the consultation and prevents the recommendation from coming before listening.

Choice talk

The first step is to say clearly that there is more than one reasonable path. Phrases such as "there are two medications that work well, and the choice between them depends a lot on your routine and what you value" open space for the person to take part. Many people arrive thinking the doctor already knows the right answer; naming the choice changes that expectation.

It is also worth naming what is outside the choice. Being in treatment is what protects most; the question is which treatment path to follow. This distinction prevents the person from leaving the consultation thinking the decision is between treating or leaving it for later. A short sentence settles it: "the decision is between two paths that work, and we will choose together what fits your life best".

Option talk

Here the information comes in, in plain language, organized by what matters for the person's life. A useful structure:

• How each medication is taken and how often the person needs to go to the service at the start.
• What each one does to intense craving and to withdrawal symptoms.
• What the main risks are, including at the start and at any eventual exit.
• What is known about staying in treatment with each one.
• What happens if the first choice does not work.

Decision support tools help people feel more informed and more confident about their values, according to the Cochrane review on the topic (Stacey et al., 2017). Even without a formal tool, a sheet with the options side by side already organizes the conversation.

Decision talk

Only then comes the question about preferences: "what weighs more for you?". The decision can come out in the same consultation or wait until the next one. The person may also prefer that the doctor recommend; that is legitimate, as long as the recommendation takes into account what they said. The post about empathy and clinical reasoning in the consultation shows how listening improves the quality of the data you use to decide.

Values and routine: what the person brings to the table

The evidence describes averages. The person brings a concrete life. Good clinical reasoning makes the two meet.

Work, family and commuting

For the woman in the opening scene, the question about work was at the center of the decision. In many services, starting methadone requires frequent visits for supervised dosing, which can be incompatible with shifts and with caring for children. Buprenorphine, in many places, allows more flexibility in take-home doses. These arrangements vary from country to country and from service to service, and so they need to be asked about and explained based on the local reality.

Previous experiences

The person may already have used one of the medications, with or without supervision. A bad experience of withdrawal when starting buprenorphine, or an acquaintance who had problems with methadone, shapes the preference. Asking "what have you lived through or heard about these medications?" brings up beliefs that would otherwise stay hidden and undermine adherence.

Intensity of use and substances involved

The pattern of use also comes into it. In people who use potent synthetic opioids, such as fentanyl, starting buprenorphine calls for special care, and this can influence the choice or the path to starting. The series covers this physiological reasoning in its own post, about precipitated withdrawal when starting buprenorphine.

Long-term goals

Some people want to think about reducing the medication one day; others want stability with no deadline. Explaining that long-term maintenance treatment is what protects most, and that leaving treatment concentrates risk, helps align expectations with the evidence (Sordo et al., 2017). The post on prognostic reasoning shows how to talk about what comes next without promising too much.

The consultation from the opening scene, redone

Go back to the woman who asked which medication would let her keep working. A better version of the consultation starts with the conversation about the choice: "there are two medications that work well; before I talk about them, tell me what your week looks like". She describes shifts that change, a long trip to the service and the worry of having to explain absences at work.

With this information, the conversation about the options changes shape. The resident explains how starting each medication works at the local service, how many visits would be needed in the first weeks and what happens once the dose stabilizes. He talks about the ceiling effect of buprenorphine and the greater structure that methadone usually offers at the start. She says she had a very bad withdrawal when she tried to stop on her own and that she is afraid of going through that again. This information enters the decision and prepares the ground for explaining how the start is managed to avoid that suffering.

In the decision conversation, she chooses buprenorphine, but asks to think until the following week. The resident agrees, sets up a contact midweek and gives her naloxone with instructions for use. The decision did not come faster; it came more solid, because it started from her routine.

Notice what changed between the two versions of the consultation:

• The first question was about the person's life, not about the medication.
• The evidence was presented in terms of what changes in the routine, not as a ranking.
• The fear of withdrawal came up and became part of the conversation.
• The time to think was accepted, with a contact arranged and naloxone provided.

Risks that enter the conversation

A truly shared decision includes risks, not only benefits. The way of presenting them is also clinical reasoning.

Starting and leaving treatment

The mortality meta-analysis showed that the first weeks of methadone and the weeks after leaving treatment are periods of higher risk (Sordo et al., 2017). This is not a reason to avoid treatment, but to plan closer follow-up at these moments and agree on what to do if the person thinks about stopping.

Interactions and other substances

Concurrent use of other depressant substances, such as alcohol and sedatives, increases the risk with any opioid. Methadone also has drug interactions and effects on heart rhythm that call for attention. The conversation needs to name these risks without turning the consultation into a moral interrogation.

How to communicate risk without frightening or minimizing

• Use natural frequencies when you have a number with a source, and not vague terms like "rare" or "common".
• Compare with the risk of going without treatment, which is the relevant comparator.
• Explain what the team will do to reduce each risk.
• Check understanding by asking the person to explain it in their own words.

Naloxone to take home

Regardless of the medication chosen, offering naloxone and explaining how to use it is part of care. The WHO guidance for community management of overdose recommends that people at higher risk of witnessing an overdose have access to it (WHO, 2014). The series discusses the decision about naloxone on the stretcher in its own post, about opioid toxidrome.

Table: factors that weigh on the choice

Factor	How it can favor buprenorphine	How it can favor methadone
Respiratory safety	Ceiling effect on respiratory depression	Requires more care at the start and with co-ingestions
Routine and travel	More flexibility for take-home doses in many services	Frequent supervised dosing can be a support for those who want structure
Heavy use of potent opioids	Initiation requires careful technique	A full agonist may control intense craving better
Retention	Similar at adequate doses	Higher in flexible-dose regimens in the Cochrane review
Previous experience	A good prior response weighs in favor	A good prior response weighs in favor
Interactions and heart rhythm	Less concern in general	Requires assessment and monitoring

Reasoning errors when choosing

Preference-sensitive decisions bring their own traps. Recognizing them is part of training.

Bias of one's own habit

The resident tends to recommend the medication they saw most at the service where they train. A systematic review showed that cognitive biases, such as overconfidence and anchoring, are associated with management errors in medical decisions (Saposnik et al., 2016). The antidote is to ask: "would I recommend the same thing if I trained at another service?".

Presuming the preference

It is common to presume what the person wants from social labels. The post on implicit bias in diagnosis shows how presumptions about gender, race and age enter decisions. Here, presumptions about who "can" follow a treatment also enter.

Language that closes the conversation

Terms such as "abuser" or "addict" change professionals' judgment. A randomized study showed that the term "substance abuser" led to more blame being assigned than "person with a substance use disorder" (Kelly and Westerhoff, 2010). In shared decision-making, language also defines whether the person feels like a partner or a suspect. The series addresses language and stigma in its own post.

Treating dependence as a character flaw

The brain disease model of addiction, discussed by Volkow and colleagues, helps frame medication treatment as treatment of a health condition, and not as swapping one drug for another (Volkow et al., 2014). This framing changes the tone of the conversation and the willingness to offer both options with equal seriousness.

How NEXO helps train this reasoning

NEXO presents fictional cases with a realistic clinical presentation and up to six progressive clues. Shared decision-making begins before the conversation, with well-done clinical reasoning: understanding the picture, the comorbidities and the context. Training with clues helps you notice which information changes the path and which merely confirms what you already thought.

The proximity feedback shows how close your guess came to the target diagnosis, which helps calibrate confidence. Calibrating confidence is exactly what is missing when the resident firmly recommends something that, in fact, depends on preferences. To understand the game, see what NEXO is and the about NEXO page. Usage limits are in economy.

In a group, NEXO Closer lets you discuss cases with colleagues and compare reasoning. Those who research, organize content or produce educational material can learn about NEXO Researcher, NEXO Curator and NEXO Creators. All texts are on the blog.

A simulated consultation exercise

After playing a case, imagine the diagnosis requires a choice between two reasonable approaches. Write the three conversations in a few lines: how you would present the choice, which options you would explain, and what question you would ask to find out the preference. Repeated a few times, this exercise turns shared decision-making from theory into habit.

Frequently asked questions

What is the best medication for opioid use disorder?

Both are effective treatment. The difference in retention appears in flexible-dose regimens and shrinks at adequate doses (Mattick et al., 2014). The best choice depends on the person, their routine and the service.

Is buprenorphine safer than methadone?

Buprenorphine has a ceiling effect on respiratory depression, which gives a greater safety margin (Walsh et al., 1994). Even so, co-ingestion of sedatives and alcohol raises the risk with any opioid.

Does shared decision-making mean the patient decides alone?

It means deciding together. The doctor brings the evidence and the experience; the person brings values and routine. The three-conversation model organizes this process (Elwyn et al., 2012).

What if the person asks the doctor to choose?

That is a legitimate preference. Make the recommendation taking into account what you heard and explain why, making clear that the choice can be revisited.

Can I switch medications if the first one does not work?

Switching is possible and is part of follow-up. The transition requires technique, and the series covers starting buprenorphine in its own post.

How long does treatment last?

It varies. The evidence shows that being in treatment protects and that leaving concentrates risk (Sordo et al., 2017). That is why the decision to reduce or stop should also be shared.

How do you explain the evidence without jargon?

Translate each finding into the person's routine. Instead of talking about retention in flexible-dose regimens, say that both work well when the dose is adjusted carefully and that what matters is finding the one they can keep up. Then ask them to sum up what they understood and correct whatever was left unclear.

Will this be on the exam?

The comparison between the two medications and the concept of shared decision-making appear in clinical and public health exams. The reasoning tested is usually weighing reasonable options, not memorizing regimens.

Final checklist

• I made clear that there is a choice between two reasonable options.
• I explained each option in plain language, organized around the person's routine.
• I presented the evidence without oversimplifying the difference in retention.
• I asked about work, family, commuting and previous experiences.
• I explained the risks of starting and of leaving treatment.
• I offered naloxone and explained how to use it.
• I checked understanding by asking the person to explain it in their own words.
• I used non-stigmatizing language from start to finish.

Play the case of the day on NEXO and, at the end, write how you would present the choice of approach to the person in the case.

References

1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. PMID: 24500948
2. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009. PMID: 19588333
3. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009. who.int
4. National Institute for Health and Care Excellence. Methadone and buprenorphine for the management of opioid dependence. TA114. nice.org.uk
5. Sordo L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017. PMID: 28446428
6. Santo T Jr, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021. PMID: 34076676
7. Wakeman SE, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020. PMID: 32022884
8. Walsh SL, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994. PMID: 8181201
9. Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020. PMID: 31420089
10. Elwyn G, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012. PMID: 22618581
11. Stacey D, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017. PMID: 28402085
12. Saposnik G, et al. Cognitive biases associated with medical decisions: a systematic review. BMC Med Inform Decis Mak. 2016. PMID: 27809908
13. Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? Int J Drug Policy. 2010. PMID: 20005692
14. Volkow ND, Koob G, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016. PMID: 26816013
15. World Health Organization. Community management of opioid overdose. 2014. who.int